I was always intrigued by reports of CFS patients with cancer going through remissions after chemotherapy and Rituximab. One of the more plausible theories for why it put CFS symptoms into remission for some patients is that it eradicated one of the main reservoirs for HGRV in b-cells. However, with our understanding or retroviruses, it is highly unlikely that they are the only reservoirs. The main reservoir for HIV seems to be CD4 memory t-cells http://www.nature.com/nm/journal/v7/n4/full/nm0401_404.html, but they have been found in the following types of somatic cells (not to mention germline cells) as well: follicular dendritic cells http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=52182 various types of stem cells (progenitor and hemopoetic) http://www.the-scientist.com/blog/display/57203/ astrocytes (glial cells in the brain) http://pag.aids2010.org/Abstracts.aspx?AID=6543 macrophages...and surely many other reservoirs that are yet to be discovered. In summary: So assuming that HGRV exhibits similar tropism tendencies as HIV (not really a stretch here), we can extrapolate that there are plenty of reservoirs beyond immune system cells and some organs (i.e. prostate). Despite this roadblock to eradication, one application of chemo has been successful, not by eradication but by inducing "lethal mutagenesis" - causing HIV to self-destruct using gemcitabine and decitabinehttp://www.newsmaxhealth.com/health_stories/chemotherapy_drugs_HIV/2010/08/25/344335.html. Peptide T (DAPTA) has also been claimed to be able to eliminate HIV reservoirs. There seems to be some noticeable momentum toward a combination of HAART and eradication-based approaches in the scientific community. Rituximab is really a form of chemo, so multi-targeted chemo seems to have a place in treatment. In a collaboration between Dr. Rafick-Pierre Skaly, of the Universit de Montral, Dr. Jean-Pierre Routy of the Research Institute of the McGill University Health Centre (RI-MUHC) and scientists from the National Institutes of Health (NIH) and the University of Minnesota in the United States, Dr. Skaly said: In an interview by Franoise Barr-Sinoussi, Ph.D., she summarized both the nature report of resting t-cell reservoirs and Dr. Sekaly's reports by saying: Considering Dr. Mikovits' substantial experience with cancer, I'm sure she is considering cancer drugs as a treatment for HGRV. I just don't know in what context. Hopefully using such detection approaches as the GFP-LnCap culture testing, she can track the migration of HGRV and hence find the reservoirs. This technique will detect both active and latent viruses in the body (GFP is used to track stem cell migration). I hope that she is simultaneously considering blocking replication and eradicating reservoirs with chemo-type approaches that are readily available. Considering the slower replication, "low-copy" status of HGRV versus HIV, I think eradication of reservoirs will actually have more immediate results than HAART. It has been theorized that much the damage being caused by HGRV is the dysfunction they cause by remaining intracellular, whereas HIV causes most of its damage via killing the T-cells and looking for additional cells to infect. I think stem cells also become begin to have a place in the conversation now. Cheney has only produced 3 cures out of 30+ patients, and it's not clear whether they had HGRV before. Considering the high HGRV positivity in his clinic http://www.forums.aboutmecfs.org/showthread.php?7331-Cheney-Clinic-positive-XMRV-MLV-HGRV-study, this low success rate may have something to do with HGRV. I know he does not like HAART because they kill stem cells, but I think chemo+haart followed by stem cells or variations of this approach should be considered because the stem cells would theoretically repair the damage previously done by either or both. Here is an outline of a clinical trial on a HAART+stem cell study going on at Duke: Would love to get more feedback on this.